Xenomics Appoints Bruce A. Huebner As CEO And Board Member
Xenomics, Inc. (Xenomics), a developer of trans-renal molecular diagnostic technologies, has appointed Bruce A. Huebner as chief executive officer (CEO) and board director.
Huebner has over 35 years of experience in the diagnostic industry, and has been worked for number of clinical diagnostic companies including Hybritech, Inc., Gen-Probe, Inc., Nanogen, Inc. and Osmetech Molecular Diagnostics. From 1996 to 2002, he was executive vice president and chief operating officer of Gen-Probe, Inc. Huebner was president and chief operating officer of Nanogen, Inc. From 2005 to 2008, Huebner, as president of Osmetech, successfully established Osmetech as a fully integrated business, obtaining FDA clearance for four molecular diagnostic microarray products and introducing them to the marketplace.
Related Insight
Suppliers Directory
Tecan - Leading Players in the Life Science Supply Industry
Tecan is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics.
Automation > Laboratory Instrumentation > Suppliers
Haselmeier - Self-Injection Devices
Haselmeier is dedicated to meeting the self-injection needs of pharmaceutical manufacturers and patients.
Automation > Laboratory Instrumentation > Suppliers
Finesse Solutions - Measurement and Control Technologies
California-based Finesse Solutions, LLC, leads the way in developing new measurement and control technologies, in order to enable the transition to single-use systems, bring new capabilities to existing bioreactor platforms, and harmonise global bio-process information transfer.
Automation > Laboratory Instrumentation > Suppliers
Biomedica Life Sciences - Radiopharmaceuticals Distributors
Biomedica Life Sciences S.A. is dynamically active in the health sector and has established a leading position in covering the market needs of the health industry in diagnostic and therapeutic products, specific medical devices and services.
Automation > Laboratory Instrumentation > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Laboratory Instrumentation Intelligence
Vade Mecum for Thermal Analysis
Published by SYSTAG
Automation > Laboratory Instrumentation > White Papers
Capsule Testing: Breaking-Force Tests for Empty and Filled Hard Capsules and Softgels
Published by Dr Schleuniger Pharmatron
Automation > Laboratory Instrumentation > White Papers
Finding the Right Contract Manufacturer
Published by Vetter Pharma International
Automation > Laboratory Instrumentation > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.